Gilgamesh is a pioneering early-stage biotech developing novel compounds that build upon the benefits of classic psychedelics with improvements of other components such as safety, tolerability, duration, and efficacy. Mental health worldwide has reached epidemic proportions and novel treatments have not kept pace with the urgent need to treat depression, anxiety, drug addiction and many other devastating diseases. Our purpose is to accelerate treatments and fundamentally improve mental health.
Location: United States, New York
Employees: 11-50
Total raised: $66M
Founded date: 2019
Investors 11
Show more
Funding Rounds 2
| Date | Series | Amount | Investors |
| 16.12.2022 | Series B | $39M | - |
| 06.05.2021 | Series A | $27M | - |
Mentions in press and media 10
| Date | Title | Description |
| 24.07.2026 | Pharmaceutical Frontier: Psychedelics Rise, GLP-1s Diversify, Global Innovation Thrives | The pharmaceutical industry undergoes rapid transformation. Big Pharma embraces psychedelic drugs, acquiring key innovators to treat diverse mental health conditions. This signals a new era for depression, PTSD, and anxiety therapies. Concu... |
| 19.07.2026 | The market for psychedelic drugs to treat mental health conditions gets a big buy signal | To learn more about the CNBC CFO Council, visit cnbccouncils.com/cfo Thursday’s announcement that Eli Lilly will acquire AtaiBeckley, a clinical-stage maker of psychedelic drugs, for up to $3.8 billion indicates Big Pharma’s increasing embr... |
| 25.08.2025 | AbbVie Acquires Gilgamesh’s Psychedelic MDD Program For Up To $1.2B | What You Should Know: – AbbVie and Gilgamesh Pharmaceuticals Inc. have announced a definitive agreement for AbbVie to acquire Gilgamesh’s lead investigational candidate, bretisilocin, which is in clinical development for the treatment of pa... |
| 27.03.2023 | Here are the 15 hottest startups in the psychedelics industry, according to top investors | From left: Sherry Rais, a cofounder and the CEO of Enthea; Mark Rus, the CEO of Delix Therapeutics; Jackie von Salm, a cofounder and the CSO of Psilera; Jimmy Qian, a cofounder and the president of Osmind. Sherry Rais/Enthea; Mark Rus/Delix... |
| 16.12.2022 | Gilgamesh Pharmaceuticals Raises $39M in Series B Funding | Gilgamesh Pharmaceuticals, a New York-based mental health science-focused biotechnology company, raised $39M in Series B funding. The round was led by Prime Movers Lab with additional investment from Alumni Ventures, Palo Santo, Negev Capit... |
| 15.12.2022 | Gilgamesh Pharmaceuticals Lands $39M Series B | NEW YORK, NY, Gilgamesh Pharmaceuticals today announced the closing of a $39 million Series B round of financing. >> Click here for more funding data on Gilgamesh Pharmaceuticals >> To export Gilgamesh Pharmaceuticals fundin... |
| 06.05.2021 | Gilgamesh Pharmaceuticals Snags $27M Series A | NEW YORK, NY, Gilgamesh Pharmaceuticals today announced the closing of a $27 million Series A round of funding. >> Click here for more funding data on Gilgamesh Pharmaceuticals >> To export Gilgamesh Pharmaceuticals funding ... |
| 06.05.2021 | New York-based biotech startup Gilgamesh Pharmaceuticals raises $27M Series A to develop psychedelic medicines to treat mental illness | Between 2009 and 2019, spending on mental health care in the United States increased by more than 50%, reaching $225 billion, and a Lancet Commission report estimates the global economic cost will reach $16 trillion by 2030. Gilgamesh Phar... |
| 06.05.2021 | Gilgamesh Pharmaceuticals Closes On $27 Million Series A Round | |
| - | Gilgamesh Pharmaceuticals | “We develop novel medicines that harness the therapeutic promise of psychedelics to revolutionize the treatment of mental illness” |